¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"First Response Ovulation Base InVt"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • reticulocyte response
    ±×¹°ÀûÇ÷±¸¹ÝÀÀ, ¸Á»óÀûÇ÷±¸¹ÝÀÀ
  • startle response
    ³î¶÷¹ÝÀÀ
  • startle response audiometry
    ³î¶÷¹ÝÀÀû·Â°Ë»ç
  • stereotyped response
    ÀÚµ¿¹Ýº¹¹ÝÀÀ, »óµ¿¹ÝÀÀ
  • stimulus response assessment
    ÀڱعÝÀÀÆò°¡
  • subthreshold response
    ¹®ÅιعÝÀÀ
  • systemic inflammatory response syndrome
    Àü½Å¿°Áõ¹ÝÀÀÁõÈıº
  • secondary evoked response
    ÀÌÂ÷À¯¹ß¹ÝÀÀ
  • secondary immune response
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • sensitization response
    ¹Î°¨È­¹ÝÀÀ
  • shortening response
    ´ÜÃà¹ÝÀÀ
  • sigmoid dose-response curve
    ±¸ºÒ¼±·®¹ÝÀÀ°î¼±
  • unconditioned response
    ¹«Á¶°Ç¹ÝÀÀ
  • visual evoked response
    ½Ã°¢À¯¹ß¹ÝÀÀ
  • withdrawal response
    ±Ý´Ü¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • response modulation
    ¹ÝÀÀÁ¶Á¤
  • placebo response
    ¼ÓÀÓ¾à¹ÝÀÀ
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ
  • pyramidal tract response
    ÇǶó¹Ô·Î¹ÝÀÀ, Ãßü·Î¹ÝÀÀ
  • response prevention
    ¹ÝÀÀ¿¹¹æ
  • response
    ¹ÝÀÀ
  • recruiting response
    µ¿¿ø¹ÝÀÀ
  • response rate
    ¹ÝÀÀ·ü
  • response set
    ¹ÝÀÀ¼¼Æ®
  • reticulocyte response
    ±×¹°¼¼Æ÷¹ÝÀÀ, ¸Á»óÀûÇ÷±¸¹ÝÀÀ
  • secondary evoked response
    ÀÌÂ÷À¯¹ß¹ÝÀÀ
  • secondary immune response
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • sensitization response
    ¹Î°¨¹ÝÀÀ
  • shortening response
    ´ÜÃà¹ÝÀÀ
  • startle response
    ³î¶÷¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • base (lining) applicators
    ÀÌÀå¿ë ±â±¸(ìÀíûéÄÐïÎý).
  • base curve
    ±âº»°î¼±(Ë»ËÓË­ËÛ).
  • base curve
    ±âº»¸¸°î(µµ)
  • base deficit
    ¿°±â°áÇÌ, ¿°±âºÎÁ·(ç¤ÐñÝÕ ðë).
  • base excess
    ¿°±â °úÀ×(Φí¥)
  • base excess =BE
    ¿°±â°úÀ×(ç¤ÐñΦ í¥).
  • base excess/deficit
    ¿°±â°úÀ×/°áÇÌ
  • base exchange
    ¿°±âġȯ(¡­öÇüµ).
  • base line
    ±âÁؼ±
  • base line
    ±â¼±(ÐñàÊ). ±â(Àú)¼±, ¹ÙÅÁ¼±.
  • base line data
    ±âÃÊÀÚ·á.
  • base line shift
    ±âÁؼ± À̵¿ (ÐññÞàÊ ì¹ÔÑ)
  • base line shift
    ±âÁؼ± º¯À§
  • base metal
    õ±Ý¼Ó(ôÁÐÝáÕ).
  • base metal alloy
    ºñ±Ý¼ÓÇÕ±Ý(ÞªÐÝáÕùê ÐÝ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
CI first cranial nerve
CN I to XII first to twelfth cranial nerves
D1 diagonal one; first dorsal vertebra
F1, F2 etc. first, second, etc., filial generation
FA false aneurysm; Families Anonymous; Fanconi anemia; far advanced; fatty acid; febrile antigen; femor...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
TRE 12-(O-tetradecanoylphorbol-13-acetate response element
APRF 3/acute phase response factor
CREB 4/cAMP response element-binding protein
CRE Cyclic AMP response element
ASR Acoustic startle response
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • non-precious metal alloy base metal alloy
    ºñ±Í±Ý¼Ó ÇÕ±Ý
    Co-CrÀ̳ª Ni-Cr ÇÕ±Ý µî È­ÇÐÀûÀ¸·Î ºÒ¾ÈÁ¤ÇÑ
  • ointment base
    ¿¬°í ±âÁ¦
  • orbital base
    ¾È¿Í Àú
  • plastic base
    ÇÕ¼º ¼öÁö»ó
    ÇÕ¼º ¼öÁö·Î Á¦ÀÛµÈ ÀÇÄ¡ ¶Ç´Â ±â·Ï»óÀÌ´Ù.
  • rubber base impression
    °í¹« Àλó
  • shellac base plate
    ½©¶ô º£À̽º Ç÷¹ÀÌÆ®
  • skull base
    µÎ°³ ±âÀú
  • temporary base
    ±âÃÊ»ó, ÇüÆÇ
    1. º¸Ã¶¹°À» Á¦ÀÛÇÏ´Â µ¿¾È ¿Î½º, ¼Ð¶ô, ¼öÁö µîÀ» »ç¿ëÇÏ¿© Àӽ÷Π¸¸µé¾î ÀÌ¿ëÇÏ´Â ÀÇÄ¡»ó. 2. ÀÇÄ¡¸¦ ¸¸µé¾î ÀûÀýÇÏ°Ô ¸ÂÃß´Â µ¥ À־ ÀӽûóÀ¸·Î »ç¿ëÇÏ´Â gutta
  • tooth-borne base
    Ä¡¾Æ ºÎ´ãÇü ÀÇÄ¡»ó
    ÁöÁö¸¦ ¾çÃø Áö´ëÄ¡¿¡¼­ ¾ò´Â ÀÇÄ¡»ó. Áï Á¶Á÷¿¡¼­´Â ÁöÁö¸¦ ¾òÁö ¾Ê´Â´Ù.
  • trial base
    ½ÃÀû ÀÇÄ¡»ó
  • wound base
    ̢˜
  • xanthine base
    »êƾ¿°±â, À鯾¿°±â
  • zinc phosphate cement base
    ÀÎ»ê ¾Æ¿¬ ½Ã¸àÆ® ÀÌÀå
    ÀÎ»ê ¾Æ¿¬ ½Ã¸àÆ®¸¦ »ç¿ëÇÏ¿© Ä¡¾Æ¿¡ Çü¼ºÇÑ ¿Íµ¿¿¡ base¸¦ ±î´Â °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
overall response rate <pharmacology> Sum of complete and partial tumour responses seen in a study, divided by the number of evaluable patients.
(05 Jan 1998)
target response In conditioning, any behaviour or specific response chosen by the experimenter; its frequency is intended to increase or decrease by the judicious pairing with it of a reinforcer when it occurs.
Synonym: target behaviour, target response.
(05 Mar 2000)
th1 response <immunology> An acquired immune response whose most prominent feature is high cytotoxic T lymphocyte activity relative to the amount of antibody production. The Th1 response is promoted by CD4+ Th1 T-helper cells.
See: Th2 Response.
(09 Oct 1997)
th2 response <immunology> An acquired immune response whose most prominent feature is high antibody production relative to the amount of cytotoxic T lymphocyte activity The Th2 response is promoted by CD4+ Th2 T-helper cells.
See: TO Response.
(09 Oct 1997)
early-phase response Prompt onset of symptoms following an antigenic stimulus.
(05 Mar 2000)
triple response <immunology> The vascular changes in the skin in response to mild mechanical injury, an outward spreading zone of reddening flare) followed rapidly by a weal (swelling) at the site of injury.
Redness, heat and swelling, three of the cardinal signs of inflammation, are present.
(18 Nov 1997)
evoked response An alteration in the electrical activity of a region of the nervous system through which an incoming sensory stimulus is passing; may be somatosensory (SER), auditory (BAER), or visual (VER).
See: evoked potential.
(05 Mar 2000)
evoked response audiometry A type of electrophysiologic audiometry in which electrical potentials of neural impulses from the cochlear nerve and various levels in the brain in response to acoustic stimulation are used to localise the site of a lesion causing a hearing loss.
(05 Mar 2000)
unconditioned response A response, such as salivation, which is a part of the animal or human repertoire.
Compare: conditioned response.
(05 Mar 2000)
flight or fight response See: emergency theory.
(05 Mar 2000)
late-phase response Recurrence of symptoms after an appreciable interval following challenge with an antigen; preceded by an initial early-phase response.
(05 Mar 2000)
lh response to gnrh This test measures the level of luteinising hormone in the blood after an injection of gonadotrophin releasing hormone (GNRH), normally produced in the hypothalamus. This will test the ability of the pituitary gland to respond by measuring one of the pituitary glands byproducts, luteinising hormone. This test is used to differentiate hypogonadism (ovary or testes) into primary hypogonadism (problem is with the ovary or testes) or secondary hypogonadism (problem is with the pituitary gland or the hypothalamus).
(27 Sep 1997)
lymphoproliferative response <haematology, immunology> A specific immune response that entails rapid T-cell replication. Standard antigens, such as tetanus toxoid, that elicit this response are used in lab tests of immune competence.
(13 Nov 1997)
acid-base balance The normal balance between acid and base in the blood plasma, expressed in the hydrogen ion concentration or pH, resulting from the relative amounts of acidic and basic materials ingested and produced by body metabolism, compared to the relative amounts of acidic and basic materials excreted from the body and consumed by body metabolism; the normal state of acid-base balance is not one of neutrality, with equal concentrations of hydrogen and hydroxyl ions, but a more alkaline state with a certain excess of hydroxyl ions.
Synonym: acid-base equilibrium.
(05 Mar 2000)
acid-base equilibrium A condition in which the net rate of acid or alkali production by the body is balanced by the net rate of acid or alkali excretion from the body, resulting in a stable concentration of hydrogen ions in the body fluids.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • first person
    Á¦ 1ÀÎĪ
  • first principle
    Á¦1¿ø¸®;±Ùº» °¡¼³
  • first quarter
    »óÇö;»óÇöÀÇ ±â°£
  • first reading
    Á¦1µ¶È¸
  • first refusal
    Á¦1¼±¸Å±Ç
  • first sergent
    À°±º»ó»ç
  • first speed
    ÀüÁø Á¦1´Ü
  • first use
    ¼±Àç »ç¿ë
  • first water
    ÃÖ¿ì·®Áú;ÃÖ¿ì¼ö;1·ù(±Þ)ÀÇ
  • private first class
    Àϵ
  • safety first
    ¾ÈÀü Á¦ÀÏ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á